Please assess the completion status of the following clinical trial:

Trial Title: A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* BMI ≥ 22kg/m\^2~* Type 2 diabetes with HbA1c between 6.5% and 10.0%~* Documented symptomatic chronic heart failure (NYHA II-IV)~* Plasma NT-proBNP \> 300pg/ml~* eGFR ≥ 45ml/min/1.73m\^2 (calculated by MDRD)~Key Exclusion Criteria:~* Pregnant or nursing (lactating) women~* Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes~* History of ketoacidosis, lactic acidosis, or hyperosmolar coma~* Symptomatic genital infection or UTI within 4 weeks of screening~* Myocardial infarction, stroke, surgery for heart disease, percutaneous coronary intervention within 3 months of randomization~* Unstable angina within 3 months of screening~* Isolated right HF due to pulmonary disease~* Patients with a mean sitting systolic blood pressure ≤ 100mmHg, at randomization~* History of lower limb amputation~* Diabetic foot ulcer at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LIK066 2.5mg (Type: EXPERIMENTAL): Eligible participants randomized to this treatment arm received the LIK066 2.5mg dose regimen once daily for 36 weeks.
- LIK066 10mg (Type: EXPERIMENTAL): Eligible participants randomized to this treatment arm received the LIK066 10mg dose regimen once daily for 36 weeks.
- LIK066 50mg (Type: EXPERIMENTAL): Eligible participants randomized to this treatment arm received the LIK066 50mg dose regimen once daily for 36 weeks.
- Empagliflozin (Type: ACTIVE_COMPARATOR): Participants randomized to this treatment arm received empagliflozin once daily for 36 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants randomized to this treatment arm received LIK066 matching placebo and empagliflozin matching placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).